Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
7,819,192
-
Total 13F shares
-
576,518
-
Share change
-
+8,592
-
Total reported value
-
$632,075
-
Price per share
-
$1.09
-
Number of holders
-
20
-
Value change
-
+$9,323
-
Number of buys
-
7
-
Number of sells
-
6
Institutional Holders of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) as of Q2 2025
As of 30 Jun 2025,
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
576,518 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, EQUITEC PROPRIETARY MARKETS, LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Schonfeld Strategic Advisors LLC, UBS Group AG, DIMENSIONAL FUND ADVISORS LP, NORTHERN TRUST CORP, and NATIONAL BANK OF CANADA /FI/.
This page lists
20
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.